A Randomized Controlled Phase 3 Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India
Condition: Rotavirus Infection of Children Interventions: Biological: TV P2-VP8; Biological: Rotarix Sponsors: PATH; Bill and Melinda Gates Foundation; SK Bioscience Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: African Health | Children | Gastroenteritis | Gastroenterology | India Health | Research | Rotavirus | Rotavirus Vaccine | Vaccines